Is Cardiac Troponin I Valuable to Detect Low-Level Myocardial Damage in Congestive Heart Failure?
- PMID: 32377078
- PMCID: PMC7199837
- DOI: 10.14744/SEMB.2018.45336
Is Cardiac Troponin I Valuable to Detect Low-Level Myocardial Damage in Congestive Heart Failure?
Abstract
Objectives: Congestive heart failure (CHF) is a heart disease with a growing incidence and prevalence. Creatine kinase-myocardial base (CK-MB) is generally used to determine myocardial damage; however, it is insufficiently sensitive to measure the relatively low level of myocardial damage that typically occurs in heart failure (HF). The use of cardiac troponins, which are far more sensitive and specific, has become common to identify myocardial damage and permits the detection of even minute amounts of damage. The aim of this study was to ascertain whether cardiac troponin I (cTnI) can be used to detect low-level myocardial damage occurring in CHF in real-life conditions.
Methods: Fifty patients with CHF symptoms (Group I) and 20 patients who were evaluated as normal (Group II) were included in this prospective study. The Framingham criteria were used to diagnose HF. Group I was divided into 3 subgroups according to the New York Heart Association classification of functional capacity: Class II, Group A; Class III, Group B, and Class IV, Group C. On the first day of admission, CK-MB and cTnI levels were measured and assessed quantitatively. The cTnI level was compared between these 3 subgroups and between Groups I and II. Linear regression analysis was performed to investigate the relationship between ejection fraction (EF) and cTnI.
Results: The mean cTnI value was 0.084±0.07 ng/mL in Group I and 0.018±0.012 ng/mL in Group II (p=0.0001). The mean cTnI value was 0.047±0.016 ng/mL, 0.080±0.048 ng/mL, and 0.175± 0.102 ng/mL in Groups A, B, and C, respectively. The difference between the subgroups of Group I was statistically significant. In addition, it was observed that there was a significant difference in the EF (%) value between Groups I and II and between Groups A, B, and C. Linear regression analysis revealed an inverse relationship between EF and cTnI (r: -0.66) (p=0.0001).
Conclusion: As the severity of HF increased, the cTnI serum level also increased. This increase was inversely related to the EF value. These results are consistent with other studies in the literature, suggesting that the cTnI level may be a useful marker in the diagnosis and evaluation of severity of HF.
Keywords: Cardiac troponin I; heart failure; troponins.
Copyright: © 2019 by The Medical Bulletin of Sisli Etfal Hospital.
Conflict of interest statement
Conflict of Interest: None declared.
Similar articles
-
Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology.Clin Chem. 2000 Mar;46(3):338-44. Clin Chem. 2000. PMID: 10702520
-
Comparison of cardiac troponin I versus T and creatine kinase MB after coronary artery bypass grafting in patients with and without perioperative myocardial infarction.Herz. 2004 Nov;29(7):658-64. doi: 10.1007/s00059-004-2543-y. Herz. 2004. PMID: 15580320 Clinical Trial.
-
Clinical importance of elevated CK-MB and troponin I levels in congestive heart failure.Adv Ther. 2006 Nov-Dec;23(6):1060-7. doi: 10.1007/BF02850226. Adv Ther. 2006. PMID: 17276973
-
Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery.Eur J Cardiothorac Surg. 1998 Jan;13(1):57-65. doi: 10.1016/s1010-7940(97)00304-7. Eur J Cardiothorac Surg. 1998. PMID: 9504731 Clinical Trial.
-
Laboratory diagnosis of patients with acute chest pain.Clin Chem Lab Med. 2000 Mar;38(3):187-97. doi: 10.1515/CCLM.2000.027. Clin Chem Lab Med. 2000. PMID: 10905753 Review.
Cited by
-
Oxidative stress signaling in the pathogenesis of diabetic cardiomyopathy and the potential therapeutic role of antioxidant naringenin.Redox Rep. 2023 Dec;28(1):2246720. doi: 10.1080/13510002.2023.2246720. Epub 2023 Sep 25. Redox Rep. 2023. PMID: 37747066 Free PMC article. Review.
-
Development of an Electrochemical Immunosensor for Detection of Cardiac Troponin I at the Point-of-Care.Biosensors (Basel). 2021 Jun 26;11(7):210. doi: 10.3390/bios11070210. Biosensors (Basel). 2021. PMID: 34206922 Free PMC article.
References
-
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. JACC. 2013;62:147–239. - PubMed
-
- de Tombe PP. Altered contractile function in heart failure. Cardiovasc Res. 1998;37:367–80. - PubMed
-
- Weil J, Eschenhagen T, Magnussen O, Mittmann C, Orthey E, Scholz H, et al. Reduction of myocardial myoglobin in bovine dilated cardiomyopathy. J Mol Cell Cardiol. 1997;29:743–51. - PubMed
-
- Ricchiuti V, Zhang J, Apple FS. Cardiac troponin I and T alterations in hearts with severe left ventricular remodeling. Clin Chem. 1997;43:990–5. - PubMed
-
- Polanczyk CA, Lee TH, Cook EF, Walls R, Wybenga D, Printy-Klein G, et al. Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain. J Am Coll Cardiol. 1998;32:8–14. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous